The Problem Approach NEOCAN‑I Pipeline Evidence Vision Partner With Us
Clinical‑Stage Oncology  ·  Boston, MA

Defining response
in cancer.

Eracan is a clinical-stage oncology company focused on understanding where therapies work best — and developing them in the biological contexts where they can achieve meaningful clinical impact.

Explore Our Pipeline → Partner With Us
4+
Active Programs
41%
ORR — Lead Asset
Ph. II
EL-001 Readiness
AI
NEOCAN‑I Platform
The Challenge

Cancer drug development is inefficient, uneven, and in need of reform.

Significant progress has been made over recent decades — yet timelines grow longer, costs escalate, and clinical results consistently fall short of expectations.

This is not only about developing better drugs. It is about understanding where and how to use them effectively — a distinction the industry has largely overlooked.

⏳
Extended Timelines

Drug development cycles stretch 10–15 years, compounded by poor patient selection and the absence of predictive biomarkers guiding trial design.

🔁
Resistance Emerges and quality of life is compromised

Even when initial responses occur, resistance develops rapidly — driven by tumor heterogeneity that standard development frameworks fail to characterize.

🎯
Missed Responders

Patients whose tumors carry the biology for response are never identified. Promising therapies are abandoned prematurely, leaving real clinical benefit unrealized.

The Eracan Perspective

Response is determined by biology — not trial design.

Because of tumor heterogeneity, the response is not uniform. The effectiveness of any therapy is governed by the tumor microenvironment — a dynamic biological system that determines whether a tumor can respond or resist.

Some tumors are inherently non-responsive. Others carry the biology required for response, but are never identified — a critical and correctable gap.

Our work focuses on repositioning existing drugs to uncover missed responders: patients whose tumors have the underlying biology for response but who are not currently identified by standard approaches.

Understanding this distinction is not academic — it is the foundation of every development decision we make.

Tumor microenvironment showing cancer cells, immune cells, stromal cells, extracellular matrix, blood vessels, lymphatic vessels, pericytes, soluble factors, metabolic factors, and physical and chemical factors
Tumor microenvironment: biological context of response
Our Approach

Where biology and opportunity intersect.

We work with drug candidates that demonstrate meaningful biological activity and evaluate them in the context of tumor biology to determine where they are most likely to succeed, how resistance can be addressed, and how response can be enhanced.

01 — WHERE TO SUCCEED
Identify Likely Responders

We analyse tumor biology to identify which patients carry the biological context for response — before committing resources to broad development programs that are set up to fail.

02 — HOW TO OVERCOME
Address Resistance Mechanisms

Understanding why tumors resist is as important as understanding why they respond. We map resistance pathways and design strategies to overcome or preempt them from the start.

03 — HOW TO ENHANCE
Amplify the Response

Once biology aligns, we identify combination strategies and synergistic pathways that can enhance, sustain, and deepen meaningful clinical responses in the right patients.

Proprietary AI Platform

NEOCAN‑I

An AI-enabled system built on in-house algorithms trained on patient-derived data — designed to analyse tumor states, predict therapeutic response, and guide development decisions with precision.

Characterise Tumor Biology & Response Patterns

Deep profiling of the tumor microenvironment across indications to map the biology governing therapeutic susceptibility.

Predict Clinical Outcomes

Model responses to monotherapy and combination strategies before entering the clinic — reducing costly late-stage failure.

Identify Resistance Mechanisms & Synergies

Map resistance pathways and identify synergistic combinations that inform program design from the earliest stages.

Early Clinical POC in Different Geographies

Generate early clinical proof-of-concept in carefully selected geographies — reducing development cost and accelerating timelines without compromising scientific or regulatory rigour.

INTEGRATED DATA MODALITIES
Tumor Microenvironment Molecular Profiling Translational Data Clinical Outcomes Patient-Derived Models
NEOCAN Intelligence

NEOCAN‑I allows us to identify non-responsive settings early and define strategies to enable response — transforming an immune desert into an immune-active environment.

🧠
AI PLATFORM VISUALIZATION
NEOCAN‑I System Diagram
Replace with platform architecture or data flow visual
Development Portfolio

A biology-guided pipeline.

Every program is selected on biological rationale and clinical relevance — aligning therapeutic potential with the contexts where response can be observed, sustained, and built upon.

EL-001
LEAD ASSET
Sarcoma — Imatinib-Resistant GIST

A repositioned topoisomerase inhibitor with established biological activity. Tumour reduction observed across multiple lesions; objective responses in resistant disease confirmed by molecular and ex vivo analysis. 41% ORR comparable to other recently approved drugs.

Phase II Ready
EL-006
ACTIVE
Metastatic Sarcoma

Selected on biological learnings from EL-001. Targets mechanisms active in metastatic spread across sarcoma subtypes where current options are inadequate.

Preclinical
EL-009
ACTIVE
Castration-Resistant Prostate Cancer

Addresses the biology of resistance in CRPC — a setting defined by treatment failure and severely limited options after first-line hormonal therapy.

Preclinical
Clinical Evidence

Translating biology into clinical outcomes.

EL-001 reflects our approach — a therapy with established biological activity, evaluated and advanced in a context where response can be observed and confirmed.

41%
Objective Response Rate
nM
Sarcoma Cell Inhibition
0
Dose-Limiting Toxicities
GIST — GASTROINTESTINAL SARCOMA
Tumour reduction across multiple lesions

EL-001 demonstrated measurable tumour reduction in multiple GIST lesions, including patients with imatinib-resistant disease where standard treatment options are exhausted.

NANOMOLAR POTENCY
Specific inhibition of sarcoma cells at nanomolar concentration

High potency at very low concentrations indicates a favourable therapeutic index and supports dose optimisation in the Phase II setting.

MOLECULAR VALIDATION
Objective responses in resistant disease, confirmed ex vivo

Findings supported by molecular and ex vivo analysis — providing early validation of the NEOCAN‑I framework for identifying biological responders in hard-to-treat settings.

MECHANISM OF ACTION — EL-001
EL-001 Mechanism of Action: DNA Top1B inhibition in sarcoma cells — showing DNA replication before and after EL-001 treatment
DNA Replication & EL-001: The Eracan Shift

EL-001 inhibits DNA Top1B — the helicase enzyme central to cancer cell proliferation. In the presence of EL-001, DNA replication is halted: triggering tumour immune activation (cytotoxic cytokine release, T-cell activation) while stopping cancer progression and accelerating cell death.

Vision & Mission

Transforming cancer care by decoding tumour heterogeneity.

Our vision is to create precisely matched therapies for every patient — built on deep biological understanding, disciplined development decisions, and unwavering translational rigour.

◐

Understand tumour biology in depth. Go beyond surface-level genomics to characterise the full biological context governing therapeutic response and resistance.

◈

Interpret data in a clinically meaningful way. Translate complex biological signals into actionable development decisions with direct patient impact.

◎

Make disciplined development decisions. Better outcomes come from better alignment between therapy, biology, and patient selection — not from chasing every opportunity.

"Better outcomes come from better alignment between therapy, biology, and patient selection."

— THE ERACAN APPROACH
Therapeutic Focus
Advancing biology-guided programs across the contexts where response can be observed and built upon.
· Sarcoma
· Prostate (CRPC)
· Resistant Disease
· Repositioning
Get In Touch

Partner with us to define
response in cancer.

We are actively seeking scientific, clinical, and investment partners who share our commitment to biology-guided oncology. Reach out to learn how we can work together.

Explore the Pipeline

Mail us at info@eracanlife.com

Boston, MA
HEADQUARTERS
Clinical-Stage
DEVELOPMENT STAGE
4+ Programs
ACTIVE PIPELINE
Phase II Ready
LEAD ASSET STATUS
The Problem Approach NEOCAN‑I Pipeline Evidence Vision Partner With Us
>